%0 Journal Article
%T Pharmacokinetic Study and Toxicity of Leukovir: A New Combined Drug for the Treatment of Multiple Sclerosis
%A Elena N. Kalinichenko
%A Irina V. Ponteleeva
%A Marina B. Golubeva
%J Advances in Biological Chemistry
%P 1-15
%@ 2162-2191
%D 2022
%I Scientific Research Publishing
%R 10.4236/abc.2022.121001
%X <span style=\"font-family:Verdana;\">Leukovir, an enteric-coated tablet, is the original drug product for
internal use. The well-known nucleosides cladribine and ribavirin are the
active ingredients of the drug product leukovir. Pharmacokinetic parameters of
the drug product for the internal use of leukovir active ingredients have been
established. The cladribine half-absorption period was </span><i><span style=\"font-family:Verdana;\">t</span></i><sub><span style=\"font-family:Verdana;\">1/2</span><i><span style=\"font-family:Verdana;\">a</span></i></sub><span style=\"font-family:Verdana;\"> = 49.5 h, </span><i><span style=\"font-family:Verdana;\">C</span></i><sub><span style=\"font-family:Verdana;\">0</span></sub><span style=\"font-family:Verdana;\"> = 276.4 ¦Ìg/ml, </span><i><span style=\"font-family:Verdana;\">C</span></i><sub><span style=\"font-family:Verdana;\">max</span></sub><span style=\"font-family:Verdana;\"> = 6.0 ¦Ìg/ml.
Distribution and accumulation parameters (</span><i><span style=\"font-family:Verdana;\">V</span><sub><span style=\"font-family:Verdana;\">d</span></sub></i><span style=\"font-family:Verdana;\">, </span><i><span style=\"font-family:Verdana;\">V</span><sub><span style=\"font-family:Verdana;\">ss</span></sub></i><span style=\"font-family:Verdana;\"> and AUC) have
indicated that the drug distribution between the blood cells and blood plasma
takes place in the same way, irrespective of the dosage form. Cladribine
half-life period is </span><i><span style=\"font-family:Verdana;\">t</span></i><sub><span style=\"font-family:Verdana;\">1/2</span><i><span style=\"font-family:Verdana;\">e</span></i></sub><span style=\"font-family:Verdana;\"> = 0.62 hours. The molecule total
clearance and average lifetime in the body in the case of subcutaneous drug
administration are approximately the same. Ribavirin is characterized by a
half-absorption period of </span><i><span style=\"font-family:Verdana;\">t</span></i><sub><span style=\"font-family:Verdana;\">1/2</span><i><span style=\"font-family:Verdana;\">a</span></i></sub><span style=\"font-family:Verdana;\"> = 0.71 h, </span><i><span style=\"font-family:Verdana;\">C</span></i><sub><span style=\"font-family:Verdana;\">0</span></sub><span style=\"font-family:Verdana;\"> = 115.6 ¦Ìg/ml and </span><i><span style=\"font-family:Verdana;\">C</span></i><sub><span style=\"font-family:Verdana;\">max</span></sub><span style=\"font-family:Verdana;\"> = 75.5 ¦Ìg/ml. Ribavirin total volume of distribution (</span><i><span style=\"font-family:Verdana;\">V</span><sub><span
%K Leukovir
%K Cladribine
%K Ribavirin
%K Multiple Sclerosis
%K Pharmacokinetics
%K Toxicity
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=114772